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The increasing incidence of melanOlna and the poor 
responsiveness of disseminated disease to conventional 
treatments call for the development of new therapeu-
tic approaches. Phenylacetate, a nontoxic differentia-
tion inducer, can suppress the growth of other neuro-
ectodermal tumors, i.e., gliomas, in laboratory models 
and in humans. This finding led us to explore the effi-
cacy of phenylacetate and related aromatic fatty acids 
in rnelanoma. Phenyl acetate and phenylbutyrate were 
found to a) induce selective cytostasis and maturation 
of cultured human melanoma cells, b) modulate the 
expression of genes implicated in tumor metastasis 
(type IV collagenase and tissue inhibitor of metallo-
proteinases-2) and immunogenicity (HLA class I); and 
c) enhance the efficacy of other agents of clinical in-
terest, including retinoids, interferon-alpha, suramin, 
and 5-aza-2'-deoxycytidine. Reflecting on the pheno-
typic heterogeneity of melanoma, the degree of bio-
D isseminated melanoma is characterized by a high mortality rate and resistance to conventional thera-pies [1]. We and others have proposed that differen-tiation therapy may provide an alternative for treat-ment of cancers that do not respond to cytotoxic 
chemotherapy [2 - 4]. Several differentiation inducers are capable of 
altering the phenotype of melanoma cells il1 vitro. These include 
retinoids, butyrate, dibutyryl adenosine 3':5'-cyclic monophos-
phate, 5-azacytidine, interferons, hexamethylene bisacetamide, di-
methyl formamide, dimethyl sulfoxide, and 12-tetradecanoylphor-
bol-13 acetate [5-9]. Unfortunately, clinical applications of these 
agents are lil~lited by. unaccept.a?le toxic~ties, concern. regardi.ng 
potential carcll1og~nesls, or mablhty to acllleve and sustam effectIve 
plasma concentrations. 
Our laboratory has recently identified sodium phenylacetate 
(NaPA) as a nontoxic differentiation inducer [10] . Phenylacetate, a 
common metabolite of phenylalanine, regulates cell growth in di-
verse organisms through phylogeny [11]. At millimolar concentra-
tions, phenylacetate selectively suppresses the growth of poorly 
differentiated embryonic plant, rodent, and human tissues [12-14]. 
We found that neoplastic cells, which are highly reminiscent of 
rapidly developing, immature tissues, are likewise vulnerable. 
NaPA promotes differentiation of human leukemic cells [10,15] 
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logic alterations induced by phenylacetatejphenylbu-
tyrate varied significantly among the tumor cell lines 
tested. Although losiug invasive capacity and tumori-
genicity in athymic mice, poorly differentiated cells 
exhibited only a marginal change in morphology, re-
mained amelanotic, and resumed growth after treat-
ment was discontinued. By contrast, treatment of mel-
anoma cells that were in a more advanced stage of 
maturation resulted in profound alterations in cell 
growth, morphology, and pigmentation consistent 
with terminal differentiation. The in vitro antitumor 
activity was observed with nontoxic, pharmacologic 
concentrations of phenylacetate and phenylbutyrate, 
suggesting potential clinical use of these drugs in the 
treatment of melanomas. Key words: cytostasisjinvasionj 
tumorigenicity jmelanogenesisjproteolysis. ] Invest Dermatol 
103:335 -340, 1994 
and brings about reversal of malignancy of various solid tumor cell 
lines, including hormone-refractory prostatic carcinoma [16], glio-
blastoma [17], neuroblastoma ([18]; Sidell et ai, unpublished), and 
rhabdomyosarcoma [19]. The central observation is that phenylace-
tate is active in some tumor models at concentrations that can be 
achieved in children and adults with no significant adverse effects 
[20,21]. Of special interest here is the fact that the activity against 
central nervous system tumors, observed in cell cultures and rat 
models, has recently been confirmed in patients with advanced dis-
ease [22]. The responsiveness of brain tumors that are refractory to 
conventional systematic therapies suggested that other neoplasms of 
neuroectodermal origin, including melanoma, may be susceptible as 
well. 
We show here that phel1ylacetate induces selective tumor cyto-
stasis and phenotypic reversion of human melanoma cells when 
used at pharmacologic nontoxic concentrations. Moreover, the 
present studies demonstrate that sodium phenylbutyrate (NaPB), a 
precursor of phenylacetate, is a potent inducer of tumor cytostasis 
and differentiation. 
MATERIALS AND METHODS 
Cell Cultures and Reagents The SKMEL 28, G361 , and RPM! mela-
noma cell lines were from the American Type Culture Collection (Rock-
ville, MD). A375 was a gift from). Fid ler (MD Anderson, Houston, TX). 
Cultures established from melanoma patients 624 mel, 501 mel , 888 mel, 
and 1011 mel, as well as normal human melanocytes, were kindly provided 
by). Weber (NCI, Bethesda, MD). All tumor cultures were maintained in 
RPM! 1640 supplemented with 10% heat-inactivated fetal bovine serum 
(Gibco Laboratories), antibiotics, and 2 mM L-glutamine. Primary melano-
cyte cultures were maintained in melanocyte basal medium (Clonetics, San 
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Diego, CA). The sodium salts of phenylacetic acid and phenylbutyric acid 
were provided by Elan Pharmaceutical Research Corp., Gainesville, GA. 
Phenylacetylglutamine (PAG) was synthesized by the reaction of phenyl-
acetychloride with glutamine [23]. Briefly, 7.5 g glutamine (Aldrich, Mil-
waukee, WI) and 8.4 g NaHC03 were added to 200 ml H20, and the 
mixture was adjusted to pH 10. While stirring vigorously, 7.5 g of pheny-
lacetylchloride (Aldrich, Milwaukee, WI) was added dropwise over the 
course of 1 h. When the last of the phenylacetylchloride had dispersed, the 
solution was adjusted to pH 2, extracted twice with hexane, and taken to 
dryness. The dried powder was rinsed with hexane and dissolved in a mini-
mum of boiling H20 . On cooling, we obtained ctystallized PAG that had 
the published melting range (melting point 101-104· C). The product 
appeared to be greater than 95% pure by high-performance liquid chroma-
tography, and the major peak co-eluted with a PAG standard used previously 
[10,16). Suramin was from Mobay Chemical Corp. (New York, NY). Inter-
feron-alpha (Roferon-A) was purchased from Hoffmann-La Roche Inc. 
(Nutley, NJ). 5-aza-2'-deoxycytidine (5A2adc) and all-trans-RA were from 
Sigma (St. Louis, MO). 
Analysis of Cell Proliferation and Viability Growth rates were deter-
mined by cell enumeration using a hemocytometer following detachment 
with trypsin ethylenediaminetetraacetic acid (EDTA), and by an enzymatic 
assay using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
[24). The two assays produced essentially the same results. DNA synthesis 
was determined by metabolic labeling with [3H) deoxythymidine (6.7 Ci/ 
mmol) (New England Nuclear). Cell viability was assessed by trypan blue 
exclusion. 
Immunocytochemistry Cells were immunostained with anti-vimentin 
monoclonal antibodies using Dako PAP kit K537 (Dako Corporation, CA). 
Invasion Through Matrigel The ability of tumor cells to degrade and 
cross tissue barriers was assessed by an ill vitro invasion assay that utilizes 
matrigel, a reconstituted basement membrane. Quantitative analysis was 
performed using Biocoat Matrigel invasion chamber (Becton Dickinson 
Labware, Bedford, MA) according to manufacturer's instructions. 
Tumor Formation in Athymic Mice Cells (5 X 105 cells per site) were 
injected subcutaneously into 4-6-week old female athymic nude mice (Di-
vision of Cancer Treatment, NCI animal Program, Frederick Cancer Re-
search Facility) . The number and size of tumors were recorded after 4 weeks. 
Quantitation of Melanin Production Melanin content was measured 
by the colorimetric method described by Whittaker [25). Briefly, tumor cells 
were plated at 1- 2 X 106 in 225-cm2 flasks, and treated for a period of 1 to 
14 d. To determine the amount of melanin produced, cells were detached at 
different time points with trypsin/EDTA and lysed (5 X 106 cells per point) 
by the addition of 0.5 ml of deionized water with two cycles of freezing and 
thawing. Perchloric acid was added to a final concentration of 0.5 N and the 
suspension was kept on the ice for 10 min, then centrifuged at 15,000 rpm 
for 5 min. The pellets were extracted twice more with 0.5 N HCL04 
followed by two extractions with a cold mixture of ethyl alcohol: ethyl ether 
(3: 1, v Iv) and final extraction with ethyl ether. The pellets were air dried, 1 
ml 0.85 N KOH was added, and then dissolved by heating to 100·C for 10 
min. After insoluble residue was pelleted and the supernatant was cooled to 
room temperature and the absorbance at 400 nm was read in a double-beam 
spectrophotometer (UV-160A) from Shimadzu Corporation (Kyoto, 
Japan). A standard curve was constructed by using synthetic melanin (Sigma) 
dissolved in hot KOH at concentrations ranging from 5 to 150 J.Lg/ m!. The 
relative melanin content is expressed as the absorbance at 400 nrn per 5 X 
106 cells/m!. 
Northern Blot Analysis Messenger RNA was extracted from treated and 
control cells by Invitrogen mRNA isolation kit (San Diego, CA). Samples (5 
J.Lg/lane) were electrophoresed through 1 % agarose/formaldehyde gels and 
blotted onto nytran membranes (Schleicher & Schuell, Keene, NH), UV-
cross-linked, and hybridization with 32P-Iabeled specific probes. Tyrosinase 
cDNA probe was kindly provided by Y. Kawakami (NCI, Bethesda, MD). 
The probe for human type IV collagenase (MMP-2. gelatinase A, E.C. 
3.4.24.24) was a peR insert of p16SPT19-1 subc10ned into the EcoRl/ 
BamHl site of Bluescript SK-(2961 Base pairs). The beta-actin probe 
(Oncor Inc., Gaithersburg, MD) was used as control to ensure equal loading 
of the samples. Probes were labeled with 32p dCTP (NEN) using a random 
primed DNA labeling kit (Ready-To-Go, Pharmacia P-L Biochemicals, 
UK). Membranes were hybridized with probes (according to the Quikhyb 
protocol provided by Stratagene, La Jolla, CA) at 68·C for 1 h and washed 
twice for 15 min each at room temperature with 2 X standard saline-citrate 
/0.1 X sodium dodecyl sulfate, and once at 60·C for 30 min with 0.1 X 
standard saline-citrate/O.l X sodium dodecylsulfate. Autoradiography 
was performed using Kodak XAR5 films at -70·C with intensifying 
screens. 
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Table I. Growth Inhibition of HUUlan MelanoUla Cells by 
NaP A and NaPB" 
ICso (mM) 
Cell Line NaPA NaPB 
624 mel 5.0 ± 0.1 1.0 ± 0.1 
501 mel 2.0 ± 0.2 0.15 ± 0.08 
888 mel 6.0 ± 0.8 1.6 ± 0.6 
1011 mel 4.7 ± 0.3 0.6 ± 0.2 
A375M 4.7 ± 0.5 0.65 ± 0.1 
SKMEL 28 5.7 ± 0.7 0.75 ± 0.07 
G361 4.4 ± 0.2 NDb 
RPMI 8.4 ± 1.3 1.5 ± 0.2 
• Data represcnts the concentration of drugs causing 50% inhibition of melanoma cdl 
proliferation (ICso, mean ± SD) after 4 d of continuous trcatment. Cell viability was 
over 95% in cultures treated with 10 mM NaPA or 3 mM NaPB. 
I ND, not determined. 
RESULTS 
Inhibition of MelanoUla Cell Proliferation by NaPA and 
NaPB Exposure of human melanoma cells to NaPA or NaPB 
resulted in a dose-dependent growth arrest evident after three or 
more days of continued treatment (Table I). The decline in cell 
proliferation was accompanied by similarly reduced DNA synthesis 
(not shown), but there was no change in cell viability. Compared to 
NaP A, N aPB was significantly more potent in inducing cytostasis, 
with 50% inhibition concentration (ICso) values ranging in seven of 
the eight tested cell lines between 0.15 and 1.0 mM, versus 2.0 - 5.7 
mM for NaPA. Reflecting on the heterogenous response of mela-
noma cells, RPMl cells were more resistant, requiring 8.4 mM 
NaPA or 1.5 mM NaPB to cause 50% inhibition of growth. How-
ever, primary normal melanocytes were even less sensitive, with 
ICso of NaPA and NaPB being 11.0 mM and 2.8 mM, respectively. 
PAG, the end-metabolite of NaPB and NaPA in humans, had no 
significant effect on tumor cell growth even at doses as high as 
10mM. 
Alterations in Morphology and Pigmentation In addition to 
affecting tumor-cell proliferation, the aromatic fatty acids induced 
morphologic alterations consistent with melanocyte differentia-
tion, including reduced nuclear to cytoplasm ratio, cell flattening, 
and enhanced expression of the cytoskeletal antigen vimentin. In 
some cases, there was development of dendritic processes and in-
creased melanogenesis. The degree of differentiation induced by 
NaPB/NaPA varied significantly depending on the phenotype of 
cells at the time treatment was initiated. For example, in A375 
cultures, which are co.mposed of amelanotic epithelial-like cells, 
only marginal morphologic changes could be induced with occa-
sional appearance of dendritic cells (not shown), whereas dramatic 
alterations were observed in the more differentiated 1011 cultures 
(Fig 1) . Within 3-4 d of NaPB treatment, 1011 cells appeared 
enlarged with a markedly increased cytoplasm to nuclear ratio. 
Moreover, the cells had a well organized cytoskeleton (evidenced by 
staining for vimentin), developed long dendritic processes, and be-
came highly melanotic (Figs 1 and 2). Compared to NaPB, NaPA 
was less effective, requiring 5 - 10 mM to increase melanogenesis by 
2-3 fold. There was, however, no toxicity observed at such high 
NaPA doses. 
Differentiation by NaPB was progressive, involved the great ma-
jority of the cell population, and became a stable trait after 2 weeks 
of continuous treatment (see below). Consistent with its relative 
potency as a cytostatic agent, NaPB was more effective than NaPA 
in promoting terminal differentiation of 1011 cells. Yet, neither 
drug was capable of inducing major morphologic changes nor mel-
anin production in A375M cultures, suggesting endogenous resist-
ance to differentiation. 
Reversibility of Antitumor Effects The stability of NaPB-in-
duced cytostasis and differentiation appeared to depend not only 011 
the cells treated but also the duration of exposure to the drug. In 
1011 cultures, the doubling time increased from 26 ± 2 h to ap-
VOL. ~03 , NO.3 SEPTEMBER 1994 
Figure 1. NaPB alters melanoma cell morphology and augments 
vitnentin expression. Photographs show melanoma 1011 cultures treated 
with NaPB for 7 d, then fixed and stained with anti-vimentin antibodies 
(B). Untreated cells are shown for comparison (A). N ote that treated cells 
are significantl y larger than controls, have mcreased cytoplasm/nuclear 
ratio, more pronounced dendritic processes, and enhanced vimentin organi-
zation. Differences in cell numbers are due to the reduced proliferative 
capacity of differentiated cell s. 
proximately 110 h following 4-d or longer treatment with 1.5 mM 
NaPB. If treatment was discontinued after 1 week, the doubling 
rime was reduced to 67 h. However, if the duration was increased to 
14 d of continuous exposure to phenyl butyrate, the replication rate 
did not change significantly upon cessation of treatment (cell dou-
bling every 96 h) . This contrasted the findings with A375M cells, 
which resumed growth in the absence of the drug (doubling time of 
20- 24 h) . 
To further evaluate the stability of the differentiated phenotype 
of 1011 cells, we determined melanin production after treatment 
was discontinued . As shown in Fig 2, 1011 mel cells exposed to 
1.5 !TIM NaPB for 14 d had 31.1 Jig/ml melanin per 106 cells; 3 d 
after treatment was stopped melanin levels further increased to 
39.9 ,ug/ml. The loss of proliferative capacity, stable morphologic 
change, and persistent melanogenesis in 1011 cells are all indicative 
of a terminal differentiation induced by N aPB. 
Loss of Invasiveness and Tumorigenicity Melanoma cells are 
high ly invasive and metastatic i"1 lIillo. Because biologically aggres-
sive cell populations could still exhibit some differentation markers, 
including melanogenesis, it was important to further examine the 
effect ofNaPB and N aPA on the malignant phenotype. The ability 
of A375M, SKMEL 28, and 1011 cells to degrade and cross tissue 
barriers was assessed by an ill lIitro invasion assay using modified 
Boyden chambers with matrigel-coated filters. After 3 - 5 d of con-
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Figure 2. NaPB enhances melanin production. In 1011 melanoma 
cells, N aPB inducc;d I?elanogenesis in a dosage- (A) and time-dependent 
manner (B). Data mdlcate the amounts (mean ± SD) of melanin accumu-
lated in treated versus control cells. The increase in melanin production was 
associated with an enhanced tyrosinase expression (see Fig 4). Maximal 
effect on melanin production (approximately sixfold increase) was observed 
with 1.5-2 mM NaPB; doses equal or higher than 3 111M were associated 
with a decline in protein synthesis and cell viability (data not shown). 
tinuous treatment with the aromatic fatty acids there was a dose-de-
pendent loss of invasive capacity (Table II). This in lIitro indication 
of phenotypic reversion correlated with loss of tumorigenicity in 
lIillo: A375M cell s treated with N aPA for one week in culture in con~rast to untreate~ cells, failed to form tumors when transplan'ted 
s.c. mto athymlc mice (Table II). Almost complete inhibition of 
invasiveness and tumorigenicity were observed with 5 mM NaPA, a' 
concentration that caused only partial cytostasis. These observations 
suggest that malignant properties such as tumorigenicity and inva-
siveness may be more sensitive to the action of phenylacetate and 
phenylbutyrate than in lIitro cell proliferation in tissue culture 
dishes. 
Modulation of Gene Expression The profound changes in 
tumor biology were associated with alterations in expression of 
genes critical to maintenance of the malignant phenotype, as well as 
those that could affect immunogenicity itl lIillO. Specifically, cells 
treated with either N aPA or NaPB had reduced levels of 3.1-kB 
mRNA transcript (Fig 3), which encodes for a 72-kDa metallopro-
teinase, type IV collagenase (gelatinase A, MMP-2) . The latter is 
involved in degradation of extracellular stroma and basal lamina 
structures, with the potential to facilitate tumor invasion and metas-
tasis [25]. As with other tumor responses, the degree of changes in 
gene expression varied among the different cell lines tested. For 
example, although 5 mM NaPA completely abrogated type IV col-
lagenase expression in SKMEL 28 cells, the specific transcript levels 
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Table II. Reduced Invasiveness In Vitro and 
Tumorigenicity in Athymic Mice 
Tumor Formationb 
Invasion Tumor Diameter, 
Treatment Through Matrigcl' mm mean 
It1 Vitro (% of control) Incidence (ran.ge) 
None 100 8/8 8.4 (2-20) 
NaPA 2.5 mM 59 ± 5.5 3/8 4.7 (0-12) 
NaPA 5 mM 22.5 ± 4 1/8 2.0 
NaPB 0.5 mM 44.1 ± 6.7 NO' NO 
NaPB 1.0 mM 16.1 ± 2.9 NO NO 
• A375 cells pre-treated for 4 d were detached and assayed for their ability to invade a 
reconstituted basement membrane using a matrigcl Invasio n Chamber. C omparable 
inhibition of invasiveness was documented with SKMEL 28 and 1011 mel cells (not 
shown). Under the experimental conditions used, 2 - 3% of the untreated cells invaded 
the matrigel within 40 h (A375M, 1011) or 24 h (SKMEL 28) , which is presented here 
as 100% invasive capacity of the melanoma cells. The data indicate the fraction 
(mean ± SO) of invasive cells in treated cultures . 
• A375M cells were pre-treated for 1 week with NaPA prior to being injected (5 X 
105 cells/animal) subcutaneously into athymic mice. Results indicate tumor incidence 
(tumor bearing/injected animals) and size of tumors, as determined 4 weeks after cell 
transplantation. 
, NO, not determined. 
were reduced only twofold in A375M cells (Fig 3) . The decrease in 
type IV collagenase in A375 and SKMEL 28 cells treated with 
NaPA or NaPB was accompanied by an increase in the expression of 
the endogenous tissue inhibitor of metalloproteinases-2 (TIMP-2) 
(Fig 3) [26,27]. This finding suggests that the net proteolytic activ-
ity may be significantly reduced by the aromatic fatty acids . In turn 
this could account, at least in part, for the decrease cellular invasive-
ness seen in the matrigel invasion assay. 
Synthesis of the differentiation marker melanin is regulated by 
the enzyme tyrosinase. As shown in Fig 4, both NaPB and NaPA 
increased (albeit to a different degree) the steady-state levels of 
tyrosinase mRNA in 1011 cells, which correlated with increased 
1 2 3 4 5 6 
Collagenase IV 
TIMP2 
~-Actin 
Figure J. NaPA and NaPB modulate collagenase type IV and TIMP-
2 gene expression. Northern blot of RNA isolated form A375M (lan es 
1-3) and SKMEL 28 cells (lanes 4-6) . Lane1, untreated A375M; lanes 2 and 
3, A375M cells treated for 4 d with 5 mM NaPA and 1.5 mM NaPB, re-
spectively; lane 4, untreated SKMEL 28; lanes 5 and 6, SKMEL 28 treated for 
4 d with 5 mM and 10 mM NaPA, respectively. The blot was hybridized 
with 32P-labeled probes for collagenase type IV and TIMP-2. The two 
mRNA species of TIMP-2 (3.5 kb and 1.1 kb) are indicated. Note that 
treatment affected the levels of the 3.5-kb mRNA in A375M cells, and the 
1.1-kb transcripts in SKMEL 28. 
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1 2 3 4 
Tyrosinase 
HLA - A3 
~-Actin 
Figure 4. Increased tyrosinase and HLA class I expression in treated 
1011 melanoma cells. Northern blot analysis of RNA isolated from 1011 
cells treated with NaPA or NaPB for 5 d. Laue 1, untreated control; lallf 2, 
7.5 mM NaPA; lane 3,1 mM NaPB; lalle 4, 2 mM NaPB. NaPB was signifi-
cantly more potent than NaPA in inducing tyrosinase and HLA expression. 
Actin levels indicate the relative amounts of RNA loaded in each lane. 
pigmentation. The Northern blot analysis indicated that the treated 
cells also had approximately twofold elevated levels of HLA-A3 
mRNA (Fig 4). The results are consistent with our previous find-
ings of increased major histocompatibility complex class I antigen 
expression in human leukemic and prostatic carcinoma cells follow-
ing treatment with NaPA [10,15] . 
Potentiation of Activity of Other Antitumor Agents Phen-
otypic heterogeneity is characteristic of tumor lesions in patients 
with melanoma. The diversity in therapeutic responses ofheteroge-
neous tumor masses would require approximate combination treat-
ment protocols. Data summarized in Fig 5 indicate that NaPA can 
significantly enhance the efficacy of other antitumor agents of clin-
ical interest. Over 700(0 inhibition of melanoma cell proliferation 
was observed when NaPA was combined with nontoxic, yet subop-
timal concentrations of interferon-alpha, all-trans retinoic acid, sur-
amin, or 5-aza-2'-deoxycytidine. The synergy with retinoic acid 
was reproduced using NaPB (0.3 -0.7 mM). For example, although 
0.3 mM N aPB and O.l,uM RA caused 10% and 48% reduction in 
1011 mel proliferation, respectively, the combination of the two 
drugs resulted in 74% decline in tumor-cell growth. 
DISCUSSION 
Melanoma is becoming an increasingly important cause of morbid-
ity and mortality worldwide, with estimated 32,000 new cases oc-
curring each year [28]. Despite major advances in cytotoxic chemo-
therapy, immunotherapy, or biologic therapy, the five years 
survival rate for individuals with disseminated disease is 14%, and 
the median survival for patients with only one site of metastasis is 
about seven months [29). In pursuit of developing new approaches 
to systemic therapy of advanced disease, we explored the efficacy of 
the differentiation inducers phenylacetate and phenylbutyrate. The 
two aromatic fatty acids have already been established as safe and 
effective in treatment of children and adults suffering from hyper-
ammonemia [19,20)' and both have recently been approved by the 
FDA as investigative new drugs for the treatment of adults with 
cancer. Our experimental data indicate that these relatively non-
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Figure 5. NaPA potentiates cytostasis induced by interferon-alpha, 
5_azacytidinc, suramin, and all-trans-RA. Melanoma 888 mel cells 
were exposed to 5 mM of NaPA alone or in combination with 300 IV /ml 
interferon-alpha. O.l/lM 5-azadC, 150 /lg/ml suramin, and 1/lM RA. Re-
sults indicate the percentage of cell growth (mean ± SO) in treated cultures 
compared to untreated controls, as determined after 5 d of continuous treat-
ment. In all cases, cell viability was over 92%. Repeated studies with A375M 
and 1011mcl cells confirmed the synergy with RA (data not shown). 
toxic compounds can induce cytostasis and phenotypic reversion of 
human melanoma cells. 
The degree for changes by NaPA and NaPB varied significantly 
among the tested cell lines, as would be expected considering the 
highly heterogeneous nature of melanoma cells. There were how-
ever several common alterations in tumor cell and molecular biol-
ogy observed, and these inclu.ded ~) reduced pr?liferative capacity; 
b) increased expressIOn of major 11lstocompaubJilty complex class I 
antigens known to affect tumor immunogenicity ill vivo; and, c) loss 
of invasiveness associated with a decline in type IV collagenase and 
enhanced expression of its endogenous inhibitor, TIMP-2 [26]. In-
dependent of its protease inhibitory activity, TIMP-2 is thought to 
suppress angiogenesis [27]. Thus, by affecting critical genes, the 
aromatic fatty acids may inhibit tumor growth, dissemination, and 
neovascu larization. 
As with other differentiation inducers [5 ,30], the ability of cells to 
undergo terminal differentiation following exposure to NaPA/ 
NaPE appeared to depend on the state of cell maturation at the time 
treatment was initiated. For example, in poorly differentiated A375 
celis, the drugs induced cytostasis with occasional appearance of 
dendritic ce lls, a slight increase in HLA expression, and loss of 
tumorigenicity in athymic mice; however, these cells remained 
nonpigmented and tyrosinase negative, and resumed growth in cul-
ture once treatment of cultures was discontinued. By contrast, ex-
posure of the more mature 1011 cells to the aromatic fatty acids 
resulted in profound and stable changes in cell growth and mor-
phology consistent with terminal differentiation. NaPB-treated 
1011 cells became heavily pigmented and polydendritic, and had 
elevated levels of tyrosinase and class I HLA mRNAs. Preliminary 
protein analysis indicates that NaPB causes a significant increase in 
both major histocompatibility complex class I and II surface anti-
gens (unpublished). These surface proteins are necessary to evoke 
proliferative and cytotoxic T-cell responses against melanomas 
[31,32] . Increased tyrosinase production and melanogenesis, in 
turn, may improve recognition by autoantigens and cause selective 
damage to malignant melanotic cells [33,34]. 
NaPB and NaPA are closely related aromatic fatty acids. Phenyl-
butyrate is metabolized by mitochondrial beta-oxidation to form 
phenylacetate (35] . Phenyl acetate, in turn, can be converted back to 
phenyl butyrate through the action of medium-chain fatty acid 
e10ngase (36]. Reminiscent of other differentiation inducers such as 
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retinoids and vitamin D derivatives [30], NaPA and NaPB were 
recently found to activate a member of the nuclear steroid receptor 
superfamily, which functions as a ligand-activated transcriptional 
factor (unpublished data). In addition, both compounds can inhibit 
the mevalonate pathway of cholestero l synthesis, and thus interfere 
with post-translational processing of proteins critical to signal 
transduction and mitogenesis [37]. At growth-inhibitory concen-
trations, NaPB and N aPA also alter the pattern of DNA methyla-
tion, an epigenetic mechanism controlling the transcription of 
various eukaryotic genes. N aPB's ability to activate the expression 
of otherwise dormant methylation-dependent genes was docu-
mented in experimental models and in humans ((15,38,39]; Bar-
Ner and Samid, unpublished). Thus, NaPA aJld NaPB may affect 
some common pathways leading to restored growth control and cell 
maturation. Consistent with this hypothesis, there was a direct 
correlation between the sensitivity of melanoma cell lines to NaPA 
and NaPB (see Table II). 
Our findings with melanoma cells lines indicate, however, that 
N aPB is a more potent modulator of gene expression aJld cell biol-
ogy compared to N aPA. The relative potency was confirmed in 
various hematopoietic and solid tumors including lymphomas, 
gliomas, and aden<:,carcinomas of the prostate, breast, ovaries, lung, 
and co~~n. (unpubhshed data). The latter could be due to the higher 
hpoph,hc,ty of NaPB, or be related to some differences in mecha-
nisms of action. It is possible that, prior to being metabolized to 
phenylacetate, phenylbutyrate may act in aJl analogous way to the 
short fatty acid, butyrate, a well-characterized differentiation in-
ducer with therapeutic potential. There are, however, several dif-
ferences in tumor responses to phenylbutyrate versus butyrate. In 
contrast to NaPB, butyrate failed to induce, and in some cases even 
inhibited tyrosinase activity and melanization of melanoma cells [7]. 
Furthermore, although phenylbutyrate increased vimentin organi-
zation in human melanoma cells, butyrate was reported to decrease 
vimentin expression in rat sarcoma cells (40] . Additional unique 
attributes of phenyl butyrate with potential clinical implications in-
clude its exten~ed half-life (1 - 2 h, versus minutes for butyrate), 
and the converSIOn to phenylacetate, itself a cytostatic and differen-
tiation inducer. Before excretion in the urine, phenylacetate must 
first be conju!?ated with glutamine to form PAG. High rates of 
urinary exc.retlon of P AG associated with NaPA-related therapies, 
can benefiCIally deplete plasma glutanline, the amino acid critical to 
tumor growth (41]. 
It appears therefore that phenylbutyrate and phenylacetate induce 
melanoma cells differentiation at nontoxic, pharmacologic concen-
trations and thus may be of value in management of this fatal dis-
ease. In. developing these drugs for clinical use, it will be important 
to conSIder the heterogeneity of melaJlomas. Metastatic melamona 
cells vary widely in their growth rate, morphology and degree of 
pigmentation; such diversity was observed in different metastases 
and even among cells within a single lesion [42]. In view of the 
re~ersibility of effect seen with poorly differentiated subpopulations 
It IS lIkely that prolonged duration of treatment would be required 
to benefit patients. Enhanced surface-antigen expression aJld re-
duced production of tumor-secreted immunosuppression factors 
[16] cou ld eventually result in tumor rejection by the host immune 
system. In cases where it might be necessary to target highly diver-
gent tumor-cell populations, the aromatic fatty acids could be com-
bined with other antitumor agents to enhance efficacy, minimize 
adverse effects, and prevent disease relapse. To this end, we have 
demonstrated the potential of combining NaPA with other differ-
entiation inducers (retinoids) , DNA h ypomethylating drugs, 5-aza-
2'-deoxycytidine, growth factor antagonists (suramin), and cyto-
kines (interferons). 
Both N aPA and NaPB are currently in clinical trials at the NCI. 
Ongoing phase I studies with NaPA, involving primarily patients 
with malignant gliomas and hormone-refractory prostate cancer, 
indicate that therapeutic levels can be achieved with no significant 
adverse effects and result in clinical improvement in patient with 
advanced disease [22]. The potential benefit to patients with mela-
noma warrants further investigation. 
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